Close Menu

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with the National Cancer Institute (NCI), in addition to agreements with three other unnamed academic and pharma groups, to demonstrate the clinical utility of Cofactor's RNA-based immune-profiling assay, Cofactor Paragon.

Under the terms of their material transfer agreement, the collaborators will use clinical specimens from several of NCI's clinical trials to validate the Paragon assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.